Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer
- 1 February 2006
- journal article
- retracted article
- Published by Wiley in Drug Development Research
- Vol. 67 (2) , 166-174
Abstract
Low molecular weight heparin (LMWH) is the agent of choice for anticoagulant therapy and prophylaxis of thrombosis and coronary syndromes. However, its therapeutic use is limited due to poor oral bioavailability. The aim of this study was to investigate the oral delivery of LMWH, ardeparin formulated with 18‐β glycyrrhetinic acid (GA), as an alternative to currently used subcutaneous (sc) delivery. Drug transport through Caco‐2 cell monolayers was monitored in the presence and absence of GA by scintillation counting and transepithelial electrical resistance. Regional permeability studies using rat intestine were performed using a modified Ussing chamber. Cell viability in the presence of various concentrations of enhancer was determined by MTT assay. The absorption of ardeparin after oral administration in rats was measured by an anti‐factor Xa assay. Furthermore, the eventual mucosal epithelial damage was histologically evaluated. Higher ardeparin permeability (∼7‐fold) compared to control was observed in the presence of 0.02 % GA. Regional permeability studies indicated predominant absorption in the duodenal segment. Cell viability studies showed no significant cytotoxicity below 0.01% GA. Ardeparin oral bioavailability was significantly increased (Frelative/s.c.=13.3%) without causing any damage to the intestinal tissues. GA enhanced the oral absorption of ardeparin both in vitro and in vivo. The oral formulation of ardeparin with GA could be absorbed in the intestine. These results suggest that GA may be used as an absorption enhancer for the oral delivery of LMWH. Drug Dev. Res. 67:166–174, 2006.Keywords
This publication has 37 references indexed in Scilit:
- Molecular Design of Sweet Tasting Compounds Based on 3β-Amino-3β-deoxy-18β-glycyrrhetinic Acid: Amido Functionality Eliciting Tremendous SweetnessChemistry Letters, 2005
- Molecular Weight Determination of Heparin and Dermatan Sulfate by Size Exclusion Chromatography with a Triple Detector ArrayBiomacromolecules, 2004
- Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosisCardiovascular Surgery, 2001
- Home treatment of deep venous thrombosis with low molecular weight heparin: Long‐term incidence of recurrent venous thromboembolismAmerican Journal of Hematology, 2001
- Cytoskeletal regulation of Caco‐2 intestinal monolayer paracellular permeabilityJournal of Cellular Physiology, 1995
- Absorption Characteristics of Chemically Modified‐Insulin Derivatives with Various Fatty Acids in the Small and Large IntestineJournal of Pharmaceutical Sciences, 1995
- Relationship between Plasma Antifactor Xa Activity and the Antithrombotic Activity of Heparins of Different Molecular MassPathophysiology of Haemostasis and Thrombosis, 1995
- Effect of Glycyrrhizinate on Dissolution Behavior and Rectal Absorption of Amphotericin B in Rabbits.Chemical and Pharmaceutical Bulletin, 1992
- Promotion of nasal absorption of insulin by glycyrrhetinic acid derivatives. I.Journal of Pharmacobio-Dynamics, 1989
- Oral administration of liposomally-entrapped heparin to beagle dogs.Chemical and Pharmaceutical Bulletin, 1982